Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
The Week's Top Stories is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street. This week we look at the debt deal, Amazon, Nvidia and C3.ai.
Bobbi Rebell, financial expert and author of Launching Financial Grownups: Live Your Richest Life by Helping Your (Almost) Adult Kids Become Everyday Money Smart, gives some tips on how to negotiate your bills to save serious money.
JPMorgan said it plans to close 21 around 25 percent of First Republic's branch location by the end of the year. The financial giant purchased the regional bank after it effectively collapsed amid an ongoing crisis in the banking sector.
